Press and Media

Home / Meetings / Press and Media
Thank you for your coverage of the AANEM Annual Meeting. Please join us at the 2025 AANEM Annual Meeting, being held Oct.29-Nov. 1 in San Francisco, California. Journalists covering the annual meeting and posting stories on social media channels are encouraged to use the official meeting hashtag #AANEMinSanFran.
Please review the Abstract Embargo Policy. For questions regarding AANEM Annual Meeting policies, please email communications@aanem.org.

View the latest AANEM Achievement Award winners, the American Neuromuscular Foundation (ANF) Abstract Award winners, and the latest AANEM news articles on News Express.

Questions? Check out the frequently asked questions below or contact communications@aanem.org. 

Frequently Asked Questions

Q: When will be content of abstracts be viewable, as opposed to just the titles?
A: The abstract content will be available at the annual meeting during the Poster Hall hours. We do not provide abstract presenter information or slides ahead of time. All available information can be found in the AANEM Abstract Guide online when it becomes available.

Q: How do I reach out to abstract or session presenters for an interview?
A: We do not offer member contact information. To connect with abstract or session presenters, review the AANEM Annual Meeting Program when available. Find the topics of interest and connect with the presenter after their lecture or during their abstract poster session time. Currently there is no interview option for virtual attendees.

Q: When can I share information?
A: The embargo on the abstracts themselves is lifted when they have been published in Muscle & Nerve and online in the AANEM Abstract Guide. However, the additional information beyond what is in the abstract itself is still embargoed. 

AANEM requires information that goes beyond that which is contained within the abstract, e.g., the release of data not included in the abstract, discussion of the abstract done as part of a scientific presentation, etc. to be embargoed until the start of the annual meeting. Please see the Abstract Embargo Policy.

Q: Will the Abstract Award Reception feature the best posters? 
A: The Abstract Award Reception is a social hour in honor of the abstract award winners where all authors, including award winners, will be available to discuss research. 

Q: Original research is ONLY presented as posters, correct?
A: Yes - the research is presented in the Poster Hall via abstract posters.

Science News: A Study on the Epidemiology of COVID-19 Related Guillain-Barré Syndrome in the United States

Jan 30, 2025, 10:04 by Allie Happel (Admin)
Several neurological complications have been reported with COVID-19, including Guillain–Barré syndrome (GBS). Researchers looked at incidence, baseline characteristics, and in-hospital outcomes of COVID 19–associated GBS in the United States.

Submitted by: Oksana Sayko, MD
Edited by: Nakul Katyal, MD

Citation: Sharma A, Sharma A, Soubani AO. A study on the epidemiology of COVID-19-related Guillain-Barré syndrome in the United States. J Clin Neuromuscul Dis. 2024;25(4):178-183. doi:10.1097/CND.0000000000000480

Summary: Several neurological complications have been reported with COVID-19, including Guillain–Barré syndrome (GBS). Researchers looked at incidence, baseline characteristics, and in-hospital outcomes of COVID 19–associated GBS in the United States.

A retrospective analysis was conducted using the USA National Inpatient Sample (NIS) database to identify hospitalizations for COVID-19 and GBS, using International Classification of Disease. The study examined factors associated with GBS using the April–December 2020 NIS database. The NIS is a publicly available all-payer database of USA inpatient hospitalizations, providing nationally representative estimates.

     
Descriptive analysis was performed to report baseline variables, including demographic characteristics, hospital characteristics, comorbidities (asthma, diabetes mellitus, chronic obstructive pulmonary disease, and obesity), and complications (acute respiratory failure, acute kidney injury, myocardial infarction, venous thromboembolism, disseminated intravascular coagulation, and septic shock). The study also investigated the utilization of noninvasive ventilation, invasive mechanical ventilation, and extracorporeal membrane oxygenation.

Results: In total, 13,705 GBS admissions were recorded nationwide in 2020; of these, 1155 (8.43%) were associated with COVID-19. The frequency of GBS in COVID-19 admissions was 0.07%, compared with 0.08% in non–COVID-19 admissions (P = 0.8166). COVID-19 cohort with GBS had higher utilization of invasive mechanical ventilation (20.8% vs. 11.8%, P <0.001) in comparison with COVID-19 cohort without GBS. GBS admissions with COVID-19 exhibited significantly higher inpatient mortality (12.2% vs. 3%, P <0.001) compared with GBS admissions without COVID-19.
 

The study findings underscore GBS as a rare yet severe complication of COVID-19, highlighting a significant difference in mortality when compared with GBS not associated with COVID-19. 

Comments: Interesting comprehensive study on COVID-19 related GBS. This study provides the first comprehensive analysis of GBS associated with COVID-19 using a large US inpatient